ACC 2017 Late-Breaking Trials

Here is a list of the American College of Cardiology (ACC) 2017 annual meeting late-breaking clinical trials presented at ACC.17 March 17-19, in Washington, D.C. The studies are linked to articles specific to the trial presentations.

ACC.17 Opening Showcase and the Joint ACC/JACC Late-Breaking Clinical Trials
Friday, March 17

• FOURIER: Primary Results of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial

• SPIRE 1 and SPIRE 2: Safety and Cardiovascular Event Efficacy of Bococizumab Among 27,000 High-risk Patients

• SURTAVI: Transcatheter Aortic Valve Replacement With a Self-Expanding Bioprosthesis Compared With Surgical Aortic Valve Replacement in Patients at Intermediate Surgical Risk: First Results From the SURTAVI Clinical Trial

Featured Clinical Research I
Friday, March 17

• RESET-HCM: Testing Safety and Efficacy: The Randomized Exploratory Study of Exercise Training in Hypertrophic Cardiomyopathy

• S2P Study: Results of MRI-Based Screening Study of 5130 Candidates for Sports Participation

• MR-INFORM: Stress Perfusion Imaging to Guide the Management of Patients With Stable Coronary Artery Disease

• Effects of Different Front-of-Pack Food Labelling Formats on the Healthiness of Food Purchases — a Randomized Trial

• Native South American Tsimane Have the Lowest Levels of Coronary Atherosclerosis Ever Reported

• ORION 1: LDL-C Reduction From 6 to 9 Months Following Single or Second Injection of Inclisiran a Novel siRNA Compound: Primary Efficacy and Safety Outcomes of the ORION 1 Trial
 

Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials
Saturday, March 18

• EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

• GEMINI-ACS-1: A Randomized Trial Evaluating Clinically Significant Bleeding With Low-Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, for Patients After Acute Coronary Syndromes

• REACH: e-Counseling for Self-Care Adherence Adds Therapeutic Benefit for Hypertension: The REACH Trial

• CARAT: Effect of Serial Infusions of CER-001, a Pre-Beta High-Density Lipoprotein Mimetic on Coronary Atherosclerosis: Results of the CARAT Study

• EBBINGHAUS: Primary Results of EBBINGHAUS, a Cognitive Study of Patients Enrolled in the FOURIER Trial

Late-Breaking Clinical Trials
Saturday, March 18

• COMPARE-ACUTE: FFR Guided Acute Complete Revascularization Versus Culprit Lesion Only Treatment in Patients Presenting With ST-Segment Elevation Myocardial Infarction and Multi Vessel Disease

• DEFINE-FLAIR: Primary Results of DEFINE-FLAIR: A Multi-Centre, Prospective, International, Randomized, Blinded Comparison of Clinical Outcomes and Cost Efficiencies of iFR and FFR Decision-Making for Physiological Guided Coronary Revascularization

• IFR-SWEDEHEART: Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve Guided Intervention (IFR-SWEDEHEART): A Multicenter, Prospective, Registry-Based Randomized Clinical Trial

• DECISION CTO: Drug-Eluting Stent Versus Optimal Medical Therapy in Patients With Coronary Chronic Total Occlusion: DECISION CTO Randomized Trial

• ABSORB III: Everolimus-Eluting Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Disease: Two-Year Outcomes From the ABSORB III Trial
 

Featured Interventional Clinical Research II
Saturday, March 18

• ADVICE Study: Real-World Comparative Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in the United States: An Analysis From Two U.S. Registries Linked to Medicare Data

• STS/ACC TVT Registry: Comparison of In-Hospital and 1-Year Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Native Aortic Stenosis From the STS/ACC TVT Registry

• Procedural and Clinical Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis

• RAD Matrix: Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD Matrix Study

• Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Valve Repair in the United States

Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials
Sunday, March 19

• LEVO-CTS: Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery With Cardiopulmonary Bypass: Primary Results of the LEVO-CTS Trial

• Cerebral Embolic Protection Devices During Surgical Aortic Valve Replacement: A Randomized Trial From the Cardiothoracic Surgical Trials Network

• Silent Cerebral Microbleeds During TAVR: Insight From a Prospective Cerebral MRI Cohort

• RESOLVE and SAVORY: Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries

• VISION Study: Relationship Between High Sensitive Troponin T Measurements and 30-Day Mortality After Noncardiac Surgery

• SPIRE-1 and SPIRE-2 - PCSK9 inhibitor bococizumab given on top of effective statin therapy

Late-Breaking Clinical Trials
Sunday, March 19

• RE-CIRCUIT: Safety and Efficacy of Uninterrupted Anticoagulation With Dabigatran Etexilate Versus Warfarin in Patients Undergoing Catheter Ablation of Atrial Fibrillation: The RE-CIRCUIT Study

• ARISTOTLE: Digoxin and Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?

• Comparative Effectiveness of Left Atrial Appendage Occlusion Among Atrial Fibrillation Patients Undergoing Cardiac Surgery: A Report From the Society of Thoracic Surgeons Adult Cardiac Surgery Database

• GIFT of Warfarin: Benefit of Pharmacogenetic Dosing

• SPAIN Study: Randomized Placebo Controlled Trial of Closed Loop Stimulation in Recurrent Reflex Vasovagal Syncope

Featured Clinical Research III
Sunday, March 19

• Early Challenges for PSCK9 Inhibitor Prescriptions and Patients: Rejections and Rates Unfilled

• STOMP: The Effect of High-Dose Atorvastatin on Neuronal Activity and Cognitive Function

• Outcomes for 15,259 U.S. Patients With Acute MI Cardiogenic Shock (AMICS) Supported With Impella

• CVD-REAL Study: Lower Rates of Hospitalization for Heart Failure in New Users of SGLT-2 Inhibitors Versus Other Glucose Lowering Drugs — Real-World Data From Four Countries and More Than 360,000 Patients: The CVD-REAL Study

• Paroxysmal Atrial Fibrillation Is Associated With Worse Clinical Outcomes Than Persistent/Permanent Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction

• Reduction in Heart Failure Hospitalizations With Ambulatory Hemodynamic Monitoring Seen in Clinical Trials Is Maintained in the Real World

See the late-breaking trials from ACC.16 with links to stories.

TCT 2016 Late-breaking Trials and First Reports
 

For more information: accscientificsession.acc.org/Plan-Your-Program/Late-Breakers